Health-Related Quality of Life (HRQoL) / Patient Reported Outcomes (PRO) of patients with partially platinum sensitive (PPS) recurrent ovarian cancer (ROC) treated in a randomized phase III trial of trabectedin and PLD vs PLD alone (OVA301): An Exploratory Analysis.

Authors
Category Primary study
Year 2011
This article has no abstract
Epistemonikos ID: 9b50b2b989833fd408197c3357d43e39420ba54d
First added on: May 12, 2020